Imdevimab

• UNSPSC Description:

  Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases[1].

• Target Antigen:

  SARS-CoV

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/imdevimab.html

• Purity:

  95.00

• Solubility:

  10 mM in DMSO

• Smiles:

  [Imdevimab]

• References & Citations:

  [1]Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 4

• CAS Number:

  2415933-40-1